External Beam Radiotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

External beam radiotherapy (EBRT) is a cornerstone of cancer treatment that uses high-energy radiation beams—most commonly X-rays (photons) produced by a linear accelerator (linac)—directed from outside the body to destroy or damage cancer cells by causing irreparable DNA strand breaks. Radiation therapy is used in approximately 50–60% of all cancer patients at some point during their treatment, either as definitive curative treatment, as adjuvant therapy after surgery, as neo-adjuvant therapy before surgery, or as palliative therapy to relieve symptoms.

Modern EBRT is delivered with exquisite precision using advanced techniques that conformally shape the radiation dose to the three-dimensional contour of the tumour while minimising dose to adjacent organs at risk. Before treatment, patients undergo a CT planning simulation in the treatment position, with MRI and PET-CT images co-registered to the planning scan. Radiation oncologists delineate tumour volumes (GTV, CTV, PTV) and organs at risk, and medical physicists calculate the optimal beam arrangement to deliver the prescribed dose. Immobilisation devices (masks, cradles) ensure reproducible daily positioning.

EBRT is delivered as a series of daily fractions (usually Monday–Friday), allowing normal tissue to repair between treatments while delivering cumulative lethal dose to tumour cells. Treatment courses range from a single fraction for palliative bone pain to 35 fractions for curative head-and-neck or prostate cancer. A multidisciplinary tumour board—including surgical oncologist, medical oncologist, and radiation oncologist—reviews all cases to determine the optimal treatment sequence incorporating radiotherapy.

EBRT treats a broad spectrum of solid tumours. Head and neck cancers (oropharyngeal, laryngeal, nasopharyngeal, oral cavity) are frequently treated with definitive chemoradiotherapy, achieving cure rates of 60–80% for early-stage disease. Breast cancer adjuvant radiotherapy after breast-conserving surgery reduces local recurrence risk by 50–70% and improves overall survival. Prostate cancer is treated with definitive EBRT using 3D-conformal, IMRT, or stereotactic body radiotherapy (SBRT) with biochemical disease-free rates comparable to radical prostatectomy. Lung cancer—both NSCLC and SCLC—is treated with concurrent chemoradiotherapy for locally advanced disease and stereotactic ablative radiotherapy (SABR/SBRT) for early inoperable disease.

Cervical, endometrial, rectal, anal, and bladder cancers are treated with curative or adjuvant EBRT, often combined with chemotherapy as radiosensitiser. Brain tumours—including glioblastoma, anaplastic glioma, and brain metastases—are treated with EBRT following surgical resection. Lymphomas respond particularly well to radiation, with involved-field or involved-site radiotherapy forming part of combined-modality treatment. Palliative EBRT (1–10 fractions) effectively relieves bone metastasis pain, spinal cord compression, superior vena cava obstruction, and haemorrhage from tumour.

Candidates for EBRT are patients with confirmed malignancy who have been reviewed by a multidisciplinary tumour board and where radiation therapy has been recommended as part of the treatment plan. Performance status is an important consideration—patients with ECOG performance status 0–2 tolerate radical radiotherapy well, while those with ECOG 3–4 are usually considered only for short palliative courses. Organ function, particularly respiratory (for thoracic RT), renal (for certain chemotherapy combinations), and hepatic (for liver-targeted RT) status guides eligibility.

Contraindications include prior radiotherapy to the same site exceeding normal tissue tolerance, active inflammatory bowel disease (for pelvic radiotherapy), active connective tissue disorders (scleroderma, systemic lupus) which predispose to severe late tissue effects, pregnancy (first and second trimester—foetal dose must be minimised), and certain inherited radiosensitivity syndromes (ataxia telangiectasia). Implanted electronic devices (pacemakers, cochlear implants, neurostimulators) in or near the radiation field require specialist assessment and may require device relocation. Modern EBRT can be safely delivered around most implants with dose assessment.

Three-dimensional conformal radiotherapy (3D-CRT) uses multiple beams shaped to conform to the tumour in three dimensions using a multileaf collimator (MLC). Intensity-modulated radiotherapy (IMRT) uses computer-optimised variable-intensity beamlets to create dose distributions that simultaneously deliver high dose to the target and low dose to organs at risk—for example, sparing the parotid glands in head-and-neck RT to reduce xerostomia. Volumetric modulated arc therapy (VMAT) is a highly efficient IMRT variant delivering treatment in a rotating arc, reducing treatment time to 2–5 minutes.

Stereotactic body radiotherapy (SBRT/SABR) delivers ablative doses in 3–5 fractions using highly precise image-guided targeting, used for early inoperable lung cancer (achieving 85–90% local control), spinal, liver, and prostate oligometastases. Stereotactic radiosurgery (SRS/GKRS—Gamma Knife) delivers single high-dose fractions for intracranial targets including brain metastases and acoustic neuromas. Proton beam therapy offers dosimetric advantages for tumours adjacent to critical structures (paediatric tumours, chordoma, skull base tumours) by exploiting the Bragg peak, depositing maximum dose at the tumour and minimal exit dose beyond. Image-guided radiotherapy (IGRT) uses daily cone-beam CT imaging to verify patient positioning before each treatment fraction. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

EBRT achieves excellent local tumour control in many cancer types. For localised prostate cancer, IMRT/IGRT delivers 5-year biochemical control rates of 85–95% for low- to intermediate-risk disease, comparable to radical prostatectomy while preserving erectile and urinary function better in most patients. Early lung cancer treated with SBRT achieves 3-year local control rates of 85–92%. Definitive chemoradiotherapy for locally advanced head-and-neck cancer achieves 5-year overall survival of 60–70% while preserving organ function versus surgery.

For palliative indications, EBRT provides pain relief from bone metastases in approximately 60–80% of patients, with complete pain relief in 25–30%. Spinal cord compression responds in 75–80% of patients when treated promptly. Superior vena cava syndrome responds within 1–2 weeks in most cases. The non-invasive nature of EBRT, its ability to treat deep and inoperable tumours, and its amenability to combination with chemotherapy make it indispensable in multidisciplinary oncology.

Acute side effects arise during and immediately after treatment (within 6 weeks) and reflect radiation damage to proliferating normal tissues in the beam path. Skin reactions (erythema, desquamation) occur with skin-surface treatments; mucositis and dysphagia in head-and-neck radiotherapy; diarrhoea, proctitis, and cystitis in pelvic radiotherapy; oesophagitis in thoracic radiotherapy; and fatigue across all treatment sites. These are managed symptomatically and usually resolve within 4–8 weeks of completing treatment.

Late toxicity (developing months to years after treatment) is more serious and includes fibrosis, lymphoedema, xerostomia (dry mouth from salivary gland damage), bowel dysfunction (radiation enteritis, proctitis), urinary incontinence and haematuria, secondary malignancy risk (lifetime risk 0.5–1% in radiated tissues), and, for brain radiotherapy, cognitive effects. Modern IMRT and proton beam therapy significantly reduce late toxicity profiles compared to older techniques. Radiation-induced second cancers occur at a rate of approximately 0.3–1% in the radiated field over 10 years, a risk substantially outweighed by the benefit of treating the primary malignancy.

During the radiotherapy course, patients are reviewed weekly by the radiation oncology team to manage acute side effects, assess treatment response, and adjust symptom-directed supportive medications. Fatigue, the most universal side effect, peaks towards the end of treatment and in the 2 weeks following completion. Oral mucositis and dysphagia in head-and-neck patients may require enteral nutrition support via a nasogastric tube or prophylactic PEG placement.

Post-radiotherapy follow-up involves clinical review and imaging at 6–8 weeks after treatment completion to assess early response, then 3-monthly for the first 2 years and 6-monthly thereafter. PET-CT at 12 weeks is the standard imaging modality for assessing post-treatment response in head-and-neck and lymphoma. PSA monitoring at 3-monthly intervals for 2 years then 6-monthly detects biochemical recurrence after prostate cancer radiotherapy. Late side effects are monitored at every follow-up visit, and patients are referred to relevant specialists (gastroenterology for bowel symptoms, urology for urinary symptoms, physiotherapy for fibrosis and lymphoedema).

EBRT in the United States costs USD 30,000–60,000 for a full curative course (e.g., 35 fractions of prostate IMRT or head-and-neck chemoradiotherapy), including planning, treatment delivery, and on-treatment reviews. SBRT (5 fractions) costs USD 15,000–30,000. Proton beam therapy costs USD 30,000–100,000 per course due to the high cost of proton accelerator infrastructure. These costs are generally covered by health insurance for approved indications in the US and by NHS in the UK.

In India, a full course of IMRT at JCI-accredited centres such as Tata Memorial, Rajiv Gandhi Cancer Institute, or Apollo Cancer Centre costs USD 3,000–8,000. SBRT is available at USD 4,000–10,000. Proton beam therapy, available in India at Apollo Proton Cancer Centre (Chennai) and AIIMS, costs USD 15,000–35,000—approximately 60–70% less than US proton therapy prices. Thailand, Singapore, and South Korea offer comparable EBRT courses at USD 8,000–20,000. The same linear accelerator technology (Varian, Elekta) is used globally, ensuring equivalent treatment delivery quality.

Brachytherapy (internal radiotherapy) places radioactive sources directly within or adjacent to the tumour, delivering high local dose with rapid dose fall-off. High-dose-rate (HDR) brachytherapy is used as a boost in prostate, cervical, and endometrial cancers. Systemic radiotherapy using radiolabelled molecules—Lutetium-177 PSMA for metastatic prostate cancer, Iodine-131 for thyroid cancer, and DOTATATE for neuroendocrine tumours—delivers targeted radiation to disseminated disease. Radical surgery (tumour resection) may be preferred over radiotherapy for certain tumours where surgical cure rates are superior or functional outcomes are better with surgery.

For early-stage breast cancer, partial breast irradiation (using accelerated intraoperative or intracavitary brachytherapy) may be equivalent to whole breast EBRT in selected low-risk patients, with reduced treatment burden. Ablative thermal therapies (HIFU, radiofrequency ablation, microwave ablation) serve as alternatives to stereotactic radiotherapy for selected small liver and kidney tumours. Immunotherapy with immune checkpoint inhibitors is increasingly combined with radiotherapy (radioimmunotherapy) to exploit the immunostimulatory abscopal effect of radiation.